— The steelmaker fell 5% after offering worse-than-expected guidance for third-quarter earnings, with the company pointing to pricing and volume challenges. Nucor said to expect earnings between $4.10 and $4.20 per share, while analysts polled by LSEG, formerly known as Refinitiv, forecasted $4.57.— The therapeutics stock plummeted 28.
3% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on a conversion of conditional to full marketing authorization for a PTC drug to treat nonsense mutation Duchenne muscular dystrophy. Raymond James downgraded the stock to underperform from outperform following the news.— The infrastructure stock retreated more than 3% a day after it announced a secondary stock offering.